Eli Lilly’s diabetes treatment wins FDA approval

Eli Lilly’s once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide has won FDA approval.

The FDA recently approved tirzepatide to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. The new diabetes treatment will be sold under the brand name Mounjaro. Mounjaro has demonstrated efficacy in improving blood sugar, and is also proven to be more effective than other diabetes therapies in clinical studies, according to the FDA.

read more